Cover Image
Market Research Report

Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023

Published by MarketsandMarkets Product code 290171
Published Content info 183 Pages
Delivery time: 1-2 business days
Price
Back to Top
Biosimilars Market by Product (Recombinant Non-Glycosylated Proteins (Insulin, rHGH, Interferon), Glycosylated (mAb, EPO), Peptides (Glucagon, Calcitonin)), Manufacturing (In-house, Contract), Disease (Oncology, Autoimmune) - Global Forecast to 2023
Published: April 6, 2018 Content info: 183 Pages
Description

"The global biosimilars market projected to grow at a CAGR of 31.7% during the forecast period."

The biosimilars market is expected to reach USD 23.63 billion by 2023 from USD 5.95 billion in 2018, at a CAGR of 31.7%. Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness, rising incidence of chronic diseases, and strategic collaborations resulting in enhanced productivity and clinical trial activities.

"The recombinant glycosylated protein segment is anticipated to grow at the fastest growth rate during the forecast period."

The biosimilars market by product is categorized into recombinant non-glycosylated proteins, recombinant glycosylated proteins, and recombinant peptides. The recombinant glycosylated proteins segment is expected to register the highest CAGR during the forecast period. The factors driving the market for glycosylated proteins are the broad therapeutic area of these proteins; presence of biosimilar versions of monoclonal antibodies at lower prices compared to reference products; numerous biologic drugs underclass monoclonal antibody, follitropin, and erythropoietin going off-patent; and numerous products in the pipeline.

"The contract manufacturing segment is estimated to grow at a rapid rate during the analysis period."

By type of manufacturing, the biosimilars market is segmented into in-house manufacturing and contract manufacturing. The contract manufacturing segment is expected to grow at the highest CAGR during the forecast period. CMOs provide cost-saving benefits to companies in terms of facilities, equipment, and labor costs.

"Asia is estimated to register the highest CAGR during the study period."

On the basis of region, the biosimilars market is segmented into North America, Europe, Asia, and the Rest of the World (RoW). Asia is expected to grow at the highest CAGR during the forecast period. Many Asian countries such as India, China, South Korea, and Japan have emerged as potential markets for biosimilars. Many emerging economies in the region are also establishing biosimilar pathways. Moreover, leading market players are outsourcing manufacturing and R&D activities to countries in the Asia Pacific region due to the availability of highly skilled resources at lower costs. In addition to this, the low per capita consumption, rapid growth in economies, trade links, and the rise in medical tourism are accelerating the growth of the Asian market.

The primary interviews conducted for this report can be categorized as follows:

  • By Company Type - Tier 1 - 70% and Tier 2 - 30%
  • By Designation - C-level - 62%, Director-level - 21%, Others - 17%
  • By Region - North America - 50%, Europe - 20%, Asia- 30%

The key players in the biosimilars market include: Pfizer (US), Sandoz (Germany), Teva Pharmaceuticals (Israel), Amgen (US), Biocon (India), Dr. Reddy's Laboratories (India), Celltrion (South Korea), and Samsung Biologics

Research Coverage:

The report analyses the biosimilars market by products, type of manufacturing, disease, and region. Apart from a comprehensive geographic product analysis and market sizing, the report also provides a competitive landscape that covers the growth strategies adopted by industry players over the last three years. In addition, the company profiles include the product portfolios, developments, and strategies adopted by prominent market players to maintain and increase their shares in the market. Market research data, current market size, and forecast of the future trends will help key market players and new entrants to make the necessary decisions regarding product offerings, geographic focus, change in strategic approach, and levels of output to remain successful in the market.

Key Benefits of Buying the Report:

This report will enable both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help these firms, garner greater market shares. Firms purchasing the report can use any one or a combination of the below-mentioned five strategies for strengthening their market shares.

The report provides insights on the following pointers:

  • Market Penetration: Comprehensive information on the product portfolios of the top players in the biosimilars market
  • Product Development/Innovation: Detailed insights on product approvals, R&D activities, and product launches in the biosimilars market
  • Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments, and product portfolios of the leading players in the biosimilars market
  • Market Development: Comprehensive information about emerging markets. This report analyzes the market for various biosimilars across geographies
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the biosimilars market
Table of Contents
Product Code: BT 2160

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. OBJECTIVES OF THE STUDY
  • 1.2. MARKET DEFINITION
  • 1.3. MARKET SCOPE
    • 1.3.1. MARKET COVERED
  • 1.4. YEARS CONSIDERED FOR THE STUDY
  • 1.5. CURRENCY
  • 1.6. LIMITATIONS
  • 1.7. STAKEHOLDERS

2. RESEARCH METHODOLOGY

  • 2.1. SECONDARY DATA
    • 2.1.1. SECONDARY SOURCES
  • 2.2. PRIMARY DATA
    • 2.2.1. PRIMARY SOURCES
  • 2.3. MARKET SIZE ESTIMATION
    • 2.3.1. BOTTOM-UP APPROACH
    • 2.3.2. TOP-DOWN APPROACH
  • 2.4. DATA TRIANGULATION METHODOLOGY
  • 2.5. ASSUMPTIONS FOR THE STUDY

3. EXECUTIVE SUMMARY

4. PREMIUM INSIGHTS

  • 4.1. BIOSIMILARS MARKET OVERVIEW
  • 4.2. ASIA: BIOSIMILARS MARKET, BY TYPE OF PRODUCT
  • 4.3. BIOSIMILARS MARKET, BY REGION
  • 4.4. GEOGRAPHICAL SNAPSHOT: BIOSIMILARS MARKET (MAJOR COUNTRIES)

5. MARKET OVERVIEW

  • 5.1. INTRODUCTION
  • 5.2. MARKET DYNAMICS
    • 5.2.1. DRIVERS
      • 5.2.1.1. Increasing demand for biosimilar drugs due to their cost-effectiveness
      • 5.2.1.2. Rising incidence of chronic diseases
      • 5.2.1.3. Strategic collaborations resulting in enhanced productivity and clinical trial activities for biosimilars
    • 5.2.2. RESTRAINTS
      • 5.2.2.1. Complexities in manufacturing
      • 5.2.2.2. Innovative strategies by biologic drug manufacturers
    • 5.2.3. OPPORTUNITIES
      • 5.2.3.1. Growth opportunities in emerging markets
      • 5.2.3.2. New indications and patent expiry of biologic products
    • 5.2.4. CHALLENGES
      • 5.2.4.1. Stringent regulatory requirements to adversely affect investments in biosimilars

6. REGULATORY OUTLOOK

  • 6.1. NORTH AMERICA
    • 6.1.1. US
    • 6.1.2. CANADA
  • 6.2. EUROPE
  • 6.3. ASIA PACIFIC
    • 6.3.1. CHINA
    • 6.3.2. INDIA
    • 6.3.3. JAPAN
    • 6.3.4. SOUTH KOREA
  • 6.4. REST OF THE WORLD
    • 6.4.1. BRAZIL
    • 6.4.2. MEXICO
    • 6.4.3. ARGENTINA
    • 6.4.4. SAUDI ARABIA

7. BIOSIMILARS MARKET, BY PRODUCT

  • 7.1. INTRODUCTION
  • 7.2. RECOMBINANT NON-GLYCOSYLATED PROTEINS
    • 7.2.1. RECOMBINANT HUMAN GROWTH HORMONE (RHGH)
    • 7.2.2. GRANULOCYTE COLONY-STIMULATING FACTOR (FILGRASTIM)
    • 7.2.3. INSULIN
    • 7.2.4. INTERFERONS
      • 7.2.4.1. Interferon-beta
      • 7.2.4.2. Interferon-alpha
  • 7.3. RECOMBINANT GLYCOSYLATED PROTEINS
    • 7.3.1. ERYTHROPOIETIN (EPO)
    • 7.3.2. MONOCLONAL ANTIBODIES (MABS)
      • 7.3.2.1. Infliximab
      • 7.3.2.2. Rituximab
      • 7.3.2.3. Adalimumab
      • 7.3.2.4. Other monoclonal antibodies
    • 7.3.3. FOLLITROPIN
  • 7.4. RECOMBINANT PEPTIDES
    • 7.4.1. GLUCAGON
    • 7.4.2. CALCITONIN

8. BIOSIMILARS MARKET, BY TYPE OF MANUFACTURING

  • 8.1. INTRODUCTION
  • 8.2. IN-HOUSE MANUFACTURING
  • 8.3. CONTRACT MANUFACTURING

9. BIOSIMILARS MARKET, BY DISEASE

  • 9.1. INTRODUCTION
  • 9.2. ONCOLOGY
  • 9.3. CHRONIC DISEASES
  • 9.4. AUTOIMMUNE DISEASES
  • 9.5. BLOOD DISORDERS
  • 9.6. GROWTH HORMONE DEFICIENCY
  • 9.7. INFECTIOUS DISEASES
  • 9.8. OTHER DISEASES

10. BIOSIMILARS MARKET, BY REGION

  • 10.1. INTRODUCTION
  • 10.2. NORTH AMERICA
    • 10.2.1. US
    • 10.2.2. CANADA
  • 10.3. EUROPE
    • 10.3.1. GERMANY
    • 10.3.2. FRANCE
    • 10.3.3. UK
    • 10.3.4. ITALY
    • 10.3.5. SPAIN
    • 10.3.6. REST OF EUROPE
  • 10.4. ASIA
    • 10.4.1. INDIA
    • 10.4.2. CHINA
    • 10.4.3. SOUTH KOREA
    • 10.4.4. JAPAN
    • 10.4.5. REST OF ASIA
  • 10.5. REST OF THE WORLD (ROW)
    • 10.5.1. LATIN AMERICA
    • 10.5.2. PACIFIC AND OCEANIA
    • 10.5.3. MIDDLE EAST AND AFRICA

11. COMPETITIVE LANDSCAPE

  • 11.1. OVERVIEW
  • 11.2. MARKET SHARE ANALYSIS, 2016
  • 11.3. COMPETITIVE SCENARIO
    • 11.3.1. PRODUCT LAUNCHES AND PRODUCT APPROVALS
    • 11.3.2. PARTNERSHIPS, COLLABORATIONS, AND AGREEMENTS
    • 11.3.3. ACQUISITIONS
    • 11.3.4. EXPANSIONS

12. COMPANY PROFILES (Introduction, Products & Services, Strategy, & Analyst Insights, Developments, MnM View)*

  • 12.1. SANDOZ
  • 12.2. PFIZER
  • 12.3. TEVA PAHRMACEUTICAL
  • 12.4. CELLTRION
  • 12.5. BIOCON
  • 12.6. AMGEN
  • 12.7. SAMSUNG BIOLOGICS
  • 12.8. MYLAN
  • 12.9. DR. REDDY'S LABORATORIES
  • 12.10. STADA ARZNEIMITTEL AG

*Details on MarketsandMarkets view, Introduction, Product & Services, Strategy, & Analyst Insights, New Developments might not be captured in case of unlisted companies.

13. APPENDIX

  • 13.1. INSIGHTS OF INDUSTRY EXPERTS
  • 13.2. DISCUSSION GUIDE
  • 13.3. KNOWLEDGE STORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 13.4. INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE
  • 13.5. AVAILABLE CUSTOMIZATIONS
  • 13.6. RELATED REPORTS
  • 13.7. AUTHOR DETAILS

LIST OF TABLES

  • TABLE 1: MAJOR COLLABORATIONS IN THE BIOSIMILARS MARKET (2015-2018)
  • TABLE 2: LIST OF KEY BIOLOGICS UNDER THE THREAT OF PATENT EXPIRY
  • TABLE 3: STATUS OF REGULATORY PATHWAY IN NORTH AMERICA
  • TABLE 4: SUBSTITUTION STATUS IN EUROPEAN COUNTRIES
  • TABLE 5: STATUS OF REGULATORY PATHWAY IN ASIA PACIFIC
  • TABLE 6: STATUS OF REGULATORY PATHWAY IN THE ROW
  • TABLE 7: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 8: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 9: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 10: BIOSIMILARS MARKET FOR RECOMBINANT HUMAN GROWTH HORMONE, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 11: LIST OF APPROVED BIOSIMILARS FOR GRANULOCYTE COLONY-STIMULATING FACTOR PRODUCTS FROM 2013 TO 2016
  • TABLE 12: BIOSIMILARS MARKET FOR GRANULOCYTE COLONY-STIMULATING FACTOR, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 13: BIOSIMILARS MARKET FOR INSULIN, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 14: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 15: BIOSIMILARS MARKET FOR INTERFERONS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 16: BIOSIMILARS MARKET FOR INTERFERON-BETA , BY REGION, 2016-2023 (USD MILLION)
  • TABLE 17: BIOSIMILARS MARKET FOR INTERFERON-ALPHA, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 18: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 19: LIST OF APPROVED BIOSIMILARS FOR ERYTHROPOIETIN
  • TABLE 20: BIOSIMILARS MARKET FOR ERYTHROPOIETIN, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 21: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016-2023 (USD BILLION)
  • TABLE 22: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 23: PIPELINE OF INFLXIMAB
  • TABLE 24: BIOSIMILARS MARKET FOR INFLXIMAB, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 25: PIPELINE OF RITUXIMAB
  • TABLE 26: BIOSIMILARS MARKET FOR RITUXIMAB, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 27: PIPELINE OF ADLIMUMAB
  • TABLE 28: BIOSIMILARS MARKET FOR ADALIMUMAB, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 29: PIPELINE OF OTHER MONOCLONAL ANTIBODIES
  • TABLE 30: BIOSIMILARS MARKET FOR OTHER MONOCLONAL ANTIBODIES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 31: BIOSIMILARS MARKET FOR FOLLITROPIN, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 32: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 33: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 34: BIOSIMILARS MARKET FOR GLUCAGON, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 35: BIOSIMILARS MARKET FOR CALCITONIN, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 36: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 37: BIOSIMILARS MARKET FOR IN-HOUSE MANUFACTURING, BY REGION, 2016-2023 (USD BILLION)
  • TABLE 38: BIOSIMILARS MARKET FOR CONTRACT MANUFACTURING, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 39: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 40: BIOSIMILARS MARKET FOR ONCOLOGY, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 41: BIOSIMILARS MARKET FOR CHRONIC DISEASES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 42: BIOSIMILARS MARKET FOR AUTOIMMUNE DISEASES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 43: BIOSIMILARS MARKET FOR BLOOD DISORDERS, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 44: BIOSIMILARS MARKET FOR GROWTH HORMONE DEFICIENCY, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 45: BIOSIMILARS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 46: BIOSIMILARS MARKET FOR OTHER DISEASES, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 47: BIOSIMILARS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 48: NORTH AMERICA: BIOSIMILARS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 49: NORTH AMERICA: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 50: NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 51: NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 52: NORTH AMERICA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 53: NORTH AMERICA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 54: NORTH AMERICA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 55: NORTH AMERICA: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 56: LIST OF BIOSIMILARS APPROVED IN THE US
  • TABLE 57: US: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 58: US: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 59: US: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 60: US: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 61: US: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 62: US: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 63: LIST OF BIOSIMILARS APPROVED IN CANADA
  • TABLE 64: CANADA: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 65: CANADA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 66: CANADA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 67: CANADA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 68: CANADA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 69: CANADA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 70: CANADA: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 71: LIST OF BIOSIMILARS APPROVED IN EUROPE
  • TABLE 72: EUROPE: BIOSIMILARS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 73: EUROPE: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 74: EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 75: EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 76: EUROPE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 77: EUROPE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 78: EUROPE: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 79: GERMANY: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 80: GERMANY: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 81: GERMANY: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 82: GERMANY: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 83: GERMANY: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 84: FRANCE: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 85: FRANCE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 86: FRANCE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 87: FRANCE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 88: FRANCE: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 89: LIST OF BIOSIMILARS IN THE UK
  • TABLE 90: UK: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 91: UK: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 92: UK: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 93: UK: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 94: UK: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 95: ITALY: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 96: ITALY: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 97: ITALY: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 98: ITALY: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 99: ITALY: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 100: SPAIN: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 101: SPAIN: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 102: SPAIN: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 103: SPAIN: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 104: SPAIN: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 105: ROE: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 106: ROE: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 107: ROE: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 108: ROE: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 109: ROE: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 110: ASIA: BIOSIMILARS MARKET, BY COUNTRY, 2016-2023 (USD MILLION)
  • TABLE 111: ASIA: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 112: ASIA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 113: ASIA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 114: ASIA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 115: ASIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 116: ASIA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 117: ASIA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 118: ASIA: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 119: BIOLOGICS APPROVED AND MARKETED IN INDIA
  • TABLE 120: INDIA: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 121: INDIA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 122: INDIA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 123: INDIA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 124: INDIA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 125: INDIA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 126: INDIA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 127: INDIA: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 128: CHINA: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 129: CHINA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 130: CHINA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 131: CHINA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 132: CHINA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 133: CHINA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 134: CHINA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 135: CHINA: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 136: LIST OF BIOSIMILARS APPROVED IN SOUTH KOREA
  • TABLE 137: SOUTH KOREA: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 138: SOUTH KOREA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 139: SOUTH KOREA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 140: SOUTH KOREA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 141: SOUTH KOREA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 142: SOUTH KOREA: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 143: LIST OF BIOSIMILARS APPROVED IN JAPAN
  • TABLE 144: JAPAN: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 145: JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 146: JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 147: JAPAN: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 148: JAPAN: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 149: JAPAN: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 150: JAPAN: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 151: ROA: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 152: ROA: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 153: ROA: BIOSIMILARS MARKET FOR INTERFERONS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 154: ROA: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 155: ROA: BIOSIMILARS MARKET FOR MONOCLONAL ANTIBODIES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 156: ROA: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 157: ROA: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 158: ROA: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 159: ROW: BIOSIMILARS MARKET, BY REGION, 2016-2023 (USD MILLION)
  • TABLE 160: ROW: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 161: ROW: BIOSIMILARS MARKET FOR RECOMBINANT NON-GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 162: ROW: BIOSIMILARS MARKET FOR RECOMBINANT GLYCOSYLATED PROTEINS, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 163: ROW: BIOSIMILARS MARKET FOR RECOMBINANT PEPTIDES, BY TYPE, 2016-2023 (USD MILLION)
  • TABLE 164: ROW: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2016-2023 (USD MILLION)
  • TABLE 165: ROW: BIOSIMILARS MARKET, BY DISEASE, 2016-2023 (USD MILLION)
  • TABLE 166: LIST OF SIMILAR BIOTHERAPEUTIC PRODUCTS APPROVED IN LATIN AMERICA
  • TABLE 167: LATIN AMERICA : BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 168: LIST OF BIOSIMILARS APPROVED IN AUSTRALIA
  • TABLE 169: LIST OF BIOSIMILARS APPROVED IN NEW ZEALAND
  • TABLE 170: PACIFIC AND OCEANIA: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 171: MIDDLE EAST AND AFRICA: BIOSIMILARS MARKET, BY PRODUCT, 2016-2023 (USD MILLION)
  • TABLE 172: THE COMPANY'S BIOSIMILAR IN PIPELINE ARE LISTED BELOW
  • TABLE 173: THE COMPANY'S BIOSIMILAR IN PIPELINE ARE LISTED BELOW
  • TABLE 174: THE COMPANY'S BIOSIMILAR IN PIPELINE ARE LISTED BELOW
  • TABLE 175: THE COMPANY'S BIOSIMILAR IN PIPELINE ARE LISTED BELOW
  • TABLE 176: THE COMPANY'S BIOSIMILAR IN PIPELINE ARE LISTED BELOW

LIST OF FIGURES

  • FIGURE 1: RESEARCH METHODOLOGY
  • FIGURE 2: BREAKDOWN OF PRIMARY INTERVIEWS
  • FIGURE 3: BOTTOM-UP APPROACH
  • FIGURE 4: TOP-DOWN APPROACH
  • FIGURE 5: DATA TRIANGULATION
  • FIGURE 6: BIOSIMILARS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION)
  • FIGURE 7: BIOSIMILARS MARKET, BY MANUFACTURING TYPE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 8: BIOSIMILARS MARKET, BY DISEASE, 2018 VS. 2023 (USD MILLION)
  • FIGURE 9: BIOSIMILARS MARKET, BY REGION, 2018 VS. 2023 (USD BILLION)
  • FIGURE 10: RISING INCIDENCE OF CHRONIC DISEASES TO DRIVE THE GROWTH OF THE MARKET
  • FIGURE 11: RECOMBINANT GLYCOSYLATED PROTIENS SEGMENT TO ACCOUNT FOR THE LARGEST MARKET SHARE IN 2017
  • FIGURE 12: NORTH AMERICA ACCOUNTED FOR THE LARGEST SHARE IN 2017
  • FIGURE 13: INDIA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
  • FIGURE 14: BIOSIMILARS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, & CHALLENGES
  • FIGURE 15: INCREASING GERIATRIC POPULATION, BY REGION, 2015 VS. 2030
  • FIGURE 16: GLOBAL INCIDENCE OF DIABETES, BY REGION, 2017 VS. 2045
  • FIGURE 17: BIOSIMILARS MARKET, BY PRODUCT, 2018 VS. 2023 (USD MILLION)
  • FIGURE 18: IN-HOUSE MANUFACTURING SEGMENT TO DOMINATE THE BIOSIMILARS MARKET IN 2018
  • FIGURE 19: ONCOLOGY SEGMENT TO DOMINATE THE BIOSIMILARS MARKET IN 2018
  • FIGURE 20: ASIA TO REGISTER THE HIGHEST GROWTH RATE IN THE BIOSIMILARS MARKET DURING THE FORECAST PERIOD
  • FIGURE 21: NORTH AMERICA: BIOSIMILARS MARKET SNAPSHOT
  • FIGURE 22: CANCER INCIDENCE IN CANADA
  • FIGURE 23: EUROPE: BIOSIMILARS MARKET SNAPSHOT
  • FIGURE 24: ASIA: BIOSIMILARS MARKET SNAPSHOT
  • FIGURE 25: ROW: BIOSIMILARS MARKET SNAPSHOT
  • FIGURE 26: KEY DEVELOPMENTS OF MAJOR PLAYERS FROM 2015 TO 2018
  • FIGURE 27: GLOBAL BIOSIMILARS MARKET SHARE ANALYSIS, BY KEY PLAYER 2016
  • FIGURE 28: SANDOZ: COMPANY SNAPSHOT
  • FIGURE 29: PFIZER: COMPANY SNAPSHOT
  • FIGURE 30: TEVA PHARMACEUTICAL: COMPANY SNAPSHOT
  • FIGURE 31: CELLTRION: COMPANY SNAPSHOT
  • FIGURE 32: BIOCON: COMPANY SNAPSHOT
  • FIGURE 33: AMGEN: COMPANY SNAPSHOT
  • FIGURE 34: SAMSUNG BIOLOGICS: COMPANY SNAPSHOT
  • FIGURE 35: MYLAN: COMPANY SNAPSHOT
  • FIGURE 36: DR. REDDY'S LABORATORIES: COMPANY SNAPSHOT
  • FIGURE 37: STADA ARZNEIMITTEL AG: COMPANY SNAPSHOT
Back to Top